The use of multigene sequencing as a therapeutic decision tool improved outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/II tiers of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), according to results from the SAFIR02-BREAST trial.
LifeCare Alliance and the Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Center and Richard J. Solove Research Institute announced a partnership aimed at enhancing access to breast cancer screening and diagnostics for underserved individuals across Ohio.
